Up to 24% body-weight reduction at 48 weeks. The strongest results ever recorded in a Phase 2 trial.
Body-weight reduction at 48 weeks (Phase 2)
Receptor agonist (GLP-1, GIP, glucagon)
The price of US compounding pharmacies
Retatrutide is a triple agonist — it activates three different receptors that control hunger, energy expenditure, and fat metabolism. In Eli Lilly's Phase 2 trial, the highest-dose group lost an average of 24.2% of body weight at 48 weeks. That's roughly double Wegovy, and meaningfully more than Tirzepatide at the same time point.
It's not approved yet. It's in late-stage trials. We compound it under physician supervision, the same way US wellness clinics do, but at Colombian prices.
Retatrutide is the protocol we recommend when the goal is significant body-weight reduction in the shortest medically-safe window.
You have substantial weight to lose. You've tried Wegovy or Ozempic and plateaued. You want the strongest molecule the science currently knows about. You're willing to titrate slowly and work with a physician.
You have an MTC or MEN2 family history. You have active pancreatitis or gallbladder disease. You're pregnant or breastfeeding. You have severe kidney impairment. Our intake screens for all of these before we'll prescribe.
Based on the Phase 2 trial data. Individual results vary; our physician calibrates dose and titration to you.
Appetite suppression starts within the first week. Calorie intake drops without effort. Mild nausea common; resolves.
Average 6–10% body-weight loss by week 12 at standard titration. Energy stabilizes. Clothes fit differently.
12–18% body-weight loss range. Body composition shifts noticeably. Metabolic markers improve.
Phase 2 mean: 24% body weight reduction at the highest dose. Maintenance protocol designed during taper.
Wegovy hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Retatrutide hits three (GLP-1 + GIP + glucagon). The glucagon arm is what unlocks the additional fat oxidation — and why the weight-loss numbers are so much higher.
Most are GI-related and resolve with slow titration. The Phase 2 trial reported them in detail. Our physician walks you through expectations during the intake.
Nausea (≈40% at high dose) · Diarrhea · Constipation · Vomiting · Decreased appetite (the point) · Fatigue in week 1–2
Tachycardia · Increased blood pressure · Severe GI symptoms requiring dose hold · Allergic reactions (rare)
Persistent abdominal pain · Severe vomiting · Signs of pancreatitis · Any signs of allergic reaction. WhatsApp the medical team — sub-2-hour reply during business hours, 24-hour emergency line.
The price US clinics charge for compounded Retatrutide.
Of batches independently verified at Janoshik (Prague).
Reviews every protocol before any vial ships.
Our compounding pharmacy partner bills monthly. You pay for the molecule, the physician oversight, and the cold-chain delivery. That's it.
$500.000 COP / 4 weeks
10mg vial · Titration starter · MD intake included · Cold-chain shipping
$900.000 COP / 4 weeks
20mg vial · Therapeutic dose · Monthly MD check-in · Priority WhatsApp support
Retatrutide is currently investigational and not FDA-approved. Medellin Peptides.co dispenses Retatrutide via magistral compounding under individual physician prescription in compliance with Colombian regulatory frameworks. Cited weight-loss percentages reference Jastreboff et al., 2023 (NEJM) Phase 2 trial data; individual results vary. Not for use in pregnancy, breastfeeding, MTC/MEN2 family history, severe renal impairment, or active pancreatitis. Discuss your medical history with our physician during intake.